Compare GECC & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GECC | CPIX |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.6M | 92.3M |
| IPO Year | 2016 | 2007 |
| Metric | GECC | CPIX |
|---|---|---|
| Price | $6.11 | $8.67 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.75 | N/A |
| AVG Volume (30 Days) | 49.8K | ★ 94.6K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | ★ 22.06% | N/A |
| EPS Growth | N/A | ★ 58.70 |
| EPS | ★ 0.41 | N/A |
| Revenue | N/A | ★ $42,010,949.00 |
| Revenue This Year | $0.92 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.61 | ★ N/A |
| Revenue Growth | N/A | ★ 16.75 |
| 52 Week Low | $4.63 | $1.85 |
| 52 Week High | $11.45 | $9.28 |
| Indicator | GECC | CPIX |
|---|---|---|
| Relative Strength Index (RSI) | 62.23 | 65.14 |
| Support Level | $5.38 | $5.55 |
| Resistance Level | $6.34 | N/A |
| Average True Range (ATR) | 0.18 | 0.50 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 80.56 | 72.17 |
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generates both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses. The Company operates as a single reportable segment with an investment objective to generate both current income and capital appreciation through debt and equity investments and manages the business on a consolidated basis.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.